PRTN3 and rheumatoid arthritis: In addition, to assess the robustness of these findings and account for treatment-related confounding, we repeated the analysis in a sub-cohort of treatment-naïve individuals (ACPA– RA, n = 14; ACPA+ RA, n = 12) using the same thresholds.